[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Veradermics Incorporated (MANE)

Veradermics Incorporated (MANE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,533,146
  • Shares Outstanding, K 37,340
  • Annual Sales, $ 0 K
  • Annual Income, $ -69,995 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on 03/30/26
  • Next Earnings Date 06/29/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.56
  • Number of Estimates 1
  • High Estimate $-0.56
  • Low Estimate $-0.56
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.68 +71.91%
on 04/08/26
101.53 -9.11%
on 04/27/26
+26.75 (+40.82%)
since 03/27/26

Most Recent Stories

More News
Stocks Slip as Higher Oil Prices Spur Inflation Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down -0.12%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.30%. June E-mini S&P futures...

ALK : 40.94 (-1.56%)
UAL : 91.75 (-1.34%)
AMAT : 401.18 (-3.80%)
SNDK : 1,063.19 (+7.40%)
VZ : 47.51 (+2.44%)
ADI : 388.04 (-2.89%)
TXN : 269.06 (-2.92%)
$IUXX : 27,251.10 (-0.19%)
DPZ : 333.11 (-9.44%)
ZNM26 : 110-305 (-0.24%)
ESM26 : 7,198.25 (+0.05%)
NCLH : 18.33 (-0.97%)
Stocks Pressured by Higher Oil Prices

The S&P 500 Index ($SPX ) (SPY ) today is unchanged, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.10%. June E-mini S&P futures (ESM26...

AAPL : 267.04 (-1.48%)
CRWD : 456.63 (+1.90%)
VZ : 47.51 (+2.44%)
$SPX : 7,164.23 (-0.01%)
MU : 520.86 (+4.86%)
MANE : 91.07 (+34.24%)
$IUXX : 27,251.10 (-0.19%)
NQM26 : 27,399.75 (-0.13%)
DPZ : 333.11 (-9.44%)
QQQ : 664.00 (+0.02%)
CLM26 : 97.14 (+2.90%)
ZNM26 : 110-305 (-0.24%)
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss

VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating...

MANE : 91.07 (+34.24%)
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Conference call will take place on Monday, April 27, 2026 at 8:00 am ET

MANE : 91.07 (+34.24%)
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates

Enrollment completed in two pivotal trials of VDPHL01 in male patients; topline data expected from Study 302 in 1H 2026 and Study 304 confirmatory trial in 2H 2026 Enrollment...

MANE : 91.07 (+34.24%)
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions,...

MANE : 91.07 (+34.24%)
Veradermics to Participate in Upcoming March Investor Conferences

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions,...

MANE : 91.07 (+34.24%)
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss

This marks the completion of enrollment of all male Phase 3 studies of VDPHL01 in pattern hair loss, with approximately 1,000 male patients enrolled across studies ...

MANE : 91.07 (+34.24%)
Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and...

MANE : 91.07 (+34.24%)
Veradermics Announces Pricing of Upsized Initial Public Offering

Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and...

MANE : 91.07 (+34.24%)

Key Turning Points

3rd Resistance Point 75.83
2nd Resistance Point 73.41
1st Resistance Point 70.63
Last Price 91.07
1st Support Level 65.43
2nd Support Level 63.01
3rd Support Level 60.23

See More

52-Week High 101.53
Last Price 91.07
Fibonacci 61.8% 74.97
Fibonacci 50% 66.76
Fibonacci 38.2% 58.56
52-Week Low 32.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.